Skip to main content
OpenTrials
Completed

NCT Number: NCT03210363

Sero-epidemiology of Priority Arboviruses in French Guiana

Dengue is an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Pasteur de la Guyane

Cayenne, 97306, France

About this study

French Guiana is a 250,000 inhabitant's French overseas department located in South America, the epidemiology of arboviruses has recently evolved and marked by important outbreaks.

Dengue remains an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Guiana resident for at least 6 months and present during the entire study period
  • Age between 2 and 75 years old

Exclusion criteria

  • Subject under guardianship or deprived of liberty by judicial decision
  • Subject with any pathology or health problem not compatible with blood sampling

Treatment and study plan

Human biological samples

Other

Blood sample

Primary outcomes

  1. Dengue, chikungunya, zika Antibodies detection by multiplex serologic tests

    Time frame: 2 years

    Description of the virological status of individuals by Mutiplex detection of antibodies directed against dengue, chikungunya and zika arboviruses.

Secondary outcomes

  1. Seroprevalence by area and age

    Time frame: 2 years

    Estimatation of the frequency of Dengue, Chikungunya and zika infections among the general population of French Guiana by geographical area and by age class

Other outcomes

  1. Dengue infections proportion

    Time frame: 2 years

    Proportion of dengue primary and multiple infections in Guiana population.

Sponsors and collaborators

Lead sponsor

Institut Pasteur

Industry

Registry information

Acronym: EPI-ARBO

Important dates

Study start
2017
Primary completion
2017
Study completion
2020
First posted
Jul 6, 2017
Registry last updated
Sep 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.